The frequency of high-risk gene mutations (BRCA1, BRCA2, PALB2) is lower in DCIS patients compared to those with IDC, while the prevalence of moderate-risk gene variants (CHEK2, ATM) is similar in both groups [42]. This evidence concerns the gene ATM and ductal breast carcinoma in situ.